About HLA class II histocompatibility antigen, DM alpha chain
HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA) is a protein
from Homo sapiens identified by UniProt accession
P28067, 261 residues long.
MolForge cross-references it against 0 known binders and
204 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DM alpha chain |
|---|
| UniProt accession | P28067 |
|---|
| Gene | HLA-DMA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 261 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (204)
Diseases linked to this target (Open Targets).
- type 1 diabetes mellitus · score 0.38
- diabetes mellitus · score 0.35
- diabetic ketoacidosis · score 0.31
- diabetic retinopathy · score 0.31
- autoimmune disease · score 0.26
- inflammatory bowel disease · score 0.25
- diabetic neuropathy · score 0.25
- Hypoglycemia · score 0.25
- type 1 diabetes nephropathy · score 0.25
- complication · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P28067-F1 | alphafold | PREDICTED | 88.27 | — |
Amino-acid sequence (261 residues)
MGHEQNQGAA LLQMLPLLWL LPHSWAVPEA PTPMWPDDLQ NHTFLHTVYC QDGSPSVGLS EAYDEDQLFF FDFSQNTRVP RLPEFADWAQ EQGDAPAILF DKEFCEWMIQ QIGPKLDGKI PVSRGFPIAE VFTLKPLEFG KPNTLVCFVS NLFPPMLTVN WQHHSVPVEG FGPTFVSAVD GLSFQAFSYL NFTPEPSDIF SCIVTHEIDR YTAIAYWVPR NALPSDLLEN VLCGVAFGLG VLGIIVGIVL IIYFRKPCSG D
Explore HLA class II histocompatibility antigen, DM alpha chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets